iShares Nasdaq Biotechnology ETF (IBB) Shares Sold by Stratos Wealth Advisors LLC

Share on StockTwits

Stratos Wealth Advisors LLC trimmed its stake in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 5.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,504 shares of the financial services provider’s stock after selling 220 shares during the period. Stratos Wealth Advisors LLC’s holdings in iShares Nasdaq Biotechnology ETF were worth $392,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of IBB. Ellis Investment Partners LLC lifted its position in shares of iShares Nasdaq Biotechnology ETF by 10,590.0% in the 1st quarter. Ellis Investment Partners LLC now owns 1,761,815 shares of the financial services provider’s stock worth $1,761,000 after purchasing an additional 1,745,334 shares during the period. Deutsche Bank AG lifted its position in iShares Nasdaq Biotechnology ETF by 32,925.6% during the 4th quarter. Deutsche Bank AG now owns 1,683,314 shares of the financial services provider’s stock valued at $162,320,000 after acquiring an additional 1,678,217 shares during the period. State of Tennessee Treasury Department purchased a new position in iShares Nasdaq Biotechnology ETF during the 4th quarter valued at about $40,732,000. Lockheed Martin Investment Management Co. lifted its position in iShares Nasdaq Biotechnology ETF by 173.9% during the 4th quarter. Lockheed Martin Investment Management Co. now owns 417,400 shares of the financial services provider’s stock valued at $40,250,000 after acquiring an additional 265,000 shares during the period. Finally, Joseph P. Lucia & Associates LLC purchased a new position in iShares Nasdaq Biotechnology ETF during the 1st quarter valued at about $2,049,000. 67.92% of the stock is owned by hedge funds and other institutional investors.

NASDAQ IBB traded down $0.06 during trading hours on Friday, reaching $104.38. 120,158 shares of the company’s stock traded hands, compared to its average volume of 2,913,010. iShares Nasdaq Biotechnology ETF has a 52-week low of $89.01 and a 52-week high of $122.97.

ILLEGAL ACTIVITY NOTICE: “iShares Nasdaq Biotechnology ETF (IBB) Shares Sold by Stratos Wealth Advisors LLC” was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://weekherald.com/2019/05/17/ishares-nasdaq-biotechnology-etf-ibb-shares-sold-by-stratos-wealth-advisors-llc.html.

iShares Nasdaq Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Read More: Buy-Side Analysts

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.